AGILeBiotics further develops novel antibiotics
Tuesday 7 August 2018
- Life Cooperative
AGILe Biotics BV has raised the next series of investment for the development of novel antibiotics against multidrug-resistant bacteria. On the 18th of July 2018, AGILe Biotics came to an agreement for joint investment from in total five regional investors. Carduso Capital and Pharma Connect Capital became new shareholders with the recently acquired investment.
With this financial support, AGILe Biotics is further developing novel antibiotics enriching its proprietary drug pipeline. With having now also Pharma Connect Capital and Carduso Capital on board, the spin-off company aims to enter clinical studies in 2020.
One year work in two days
The antibiotic resistance increases and the treatment options decrease. The most successful strategy for introducing new antibiotics (chemical synthesis) takes a lot of time, in the range of years. This is where AGILeBiotics comes in, of course in close contact with researchers from the Centre for Sustainable Antimicrobials (CeSAM) - a collaboration of several University of Groningen research institutes and the University Medical Center Groningen, focused on tackling antimicrobial resistance - and with local life science SMEs. The patented technology platform of AGILeBiotics brings back one-year's work of synthesis to just two days. You can imagine what this does with the chance of finding new antibiotics, and thus finding new treatment options.
About AGILe Biotics
AGILe Biotics BV was launched in March 2017 as a spin-off company from the University of Groningen (UG). With a pre-seed investment received from Hanzepoort BV, RUG Houdstermaatschappij BV and Stichting ir. G.J. Smid Fonds BV in 2017, AGILe Biotics has already identified promising lead compounds showing superior activity against clinical bacterial isolates. Compared to current treatment options, those antibiotic candidates show improved activity against resistant pathogens and broader activity not only against Gram-negative, but also Gram-positive bacteria.
Focus areasLife Cooperative
Wednesday 6 February 2019
High presence talent at Meet&Greets 2019
Wednesday 30 January 2019
LIFE Cooperative: ‘An important ecosystem in the field of ..
Tuesday 15 January 2019
InnoCore Pharmaceuticals will develop contraceptive micron..
Tuesday 4 December 2018
Welcome to new start up EV Biotech
Monday 5 November 2018
Worldwide market at LIFE Cooperatives feet
Monday 3 September 2018
Lode Holding: initiator, participant and part of the Campu..
Tuesday 28 August 2018
A goldmine in Groningen: business in biobanking
Thursday 23 August 2018
Lode Holding & MercachemSyncom at the start of Campus ..
Monday 30 July 2018
Worldwide cooperation agreement InnoCore Pharmaceuticals a..
Thursday 5 July 2018
Covenant Personalized & Customized Health also signed..